JAGUAR HEALTH, INC. Royalty Expense
JAGUAR HEALTH, INC. (JAGX) reported Royalty Expense of $142.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-19
- JAGUAR HEALTH, INC. royalty expense for the quarter ending 2026-06-30 was $142.00K, a 264.10% increase year-over-year.
- JAGUAR HEALTH, INC. royalty expense for the quarter ending 2026-03-31 was $142.00K, a 264.10% increase year-over-year.
- JAGUAR HEALTH, INC. royalty expense for the quarter ending 2025-12-31 was $39.00K, a 160.00% increase year-over-year.
- JAGUAR HEALTH, INC. royalty expense for the quarter ending 2025-09-30 was $39.00K.
- JAGUAR HEALTH, INC. royalty expense for fiscal 2025 was $156.00K, a 940.00% increase from fiscal 2024.
- JAGUAR HEALTH, INC. royalty expense for fiscal 2024 was $15.00K.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.00K 10-Q · filed 2026-08-19 | $284.00K 10-Q · filed 2026-08-19 | $323.00K derived: sum of 3 quarters · filed 2026-08-19 | $362.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $142.00K 10-Q · filed 2026-05-20 | $181.00K derived: sum of 2 quarters · filed 2026-05-20 | $220.00K derived: sum of 3 quarters · filed 2026-05-20 | $259.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $78.00K derived: sum of 2 quarters · filed 2026-04-07 | $117.00K derived: sum of 3 quarters · filed 2026-08-19 | $156.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | $39.00K 10-Q · filed 2025-11-14 | $78.00K derived: sum of 2 quarters · filed 2026-08-19 | $117.00K 10-Q · filed 2025-11-14 | $132.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $39.00K 10-Q · filed 2026-08-19 | $78.00K 10-Q · filed 2026-08-19 | $93.00K derived: sum of 3 quarters · filed 2026-08-19 | |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-20 | $54.00K derived: sum of 2 quarters · filed 2026-05-20 | ||
| 2024-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $15.00K 10-K · filed 2026-04-07 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |